Taberbufamine D






Names

    • Taberbufamine D

Attributes

  • Canonical SMILES

    COC(C=C12)=CC=C2NC3([C@@](C[C@@]4([H])C[C@@H]5CC)([H])[C@@]5([H])N(C4[C@@](O)([H])C)CC3)C1=O

  • InChI

    InChI=1S/C22H30N2O3/c1-4-13-9-14-10-17-20(13)24(19(14)12(2)25)8-7-22(17)21(26)16-11-15(27-3)5-6-18(16)23-22/h5-6,11-14,17,19-20,23,25H,4,7-10H2,1-3H3/t12-,13+,14-,17-,19?,20+,22?/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 61.800000000000004
  • #RotBonds: 3
  • MW: 370.4930000000001
  • HBD: 2
  • HBA: 5
  • logP: 2.9319000000000015
  • Chemical Formula: C22H30N2O3


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. bufalina China 403123 Cai20170220

External Databases


References

  • Iboga-type alkaloids with Indolizidino[8,7-b]Indole scaffold and bisindole alkaloids from Tabernaemontana bufalina Lour. Phytochemistry, 2022 (PMID 35074605).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Butyrylcholinesterase
    • α-glucosidase inhibitory
    • Antimicrobial

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Category Property Name Predicted Value
    Absorption Caco-2 (logPaap) -4.86
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.9
    Human Oral Bioavailability 50% Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -1.81
    Distribution Blood-Brain Barrier (Central Nervous System) -2.78
    Blood-Brain Barrier Non-Penetrable
    Fraction Unbound (Human) 0.63
    Plasma Protein Binding 54.05
    Steady State Volume of Distribution 2.25
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 7.21
    Organic Cation Transporter 2 Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor -0.69
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.08
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 5.78
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Toxic
    T. Pyriformis -12.82
    Rat (Acute) 3.07
    Rat (Chronic Oral) 1.73
    Fathead Minnow 3.76
    Respiratory Disease Toxic
    Skin Sensitisation Toxic
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 466.04
    Hydration Free Energy -4.88
    Log(D) at pH=7.4 2.25
    Log(P) 2.35
    Log S -3.05
    Log(Vapor Pressure) -8.66
    Melting Point 183.23
    pKa Acid 7.09
    pKa Basic 7.81